luvixasertib   Click here for help

GtoPdb Ligand ID: 11664

Synonyms: CFI-402257 | CFI402257 | compound 24 [PMID: 27437075]
Compound class: Synthetic organic
Comment: CFI-402257 is an orally bioavailable, and somewhat selective type 1.5 inhibitor of threonine tyrosine kinase (TTK) [1-2]. TTK inhibitors are under investigation as anticancer agents. CFI-402257 induces chromosome missegregation and aneuploidy which lead to cell death. We matched CFI-402257's chemical structure to the INN 'luvixasertib' that was released in the WHO's proposed INN list 127 (21 July 2022).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 3
Rotatable bonds 9
Topological polar surface area 113.67
Molecular weight 498.24
XLogP 4.6
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES O=C(c1ccc(cc1C)c1cnn2c1nc(Oc1cccnc1)cc2NCC1CC(C1)(C)O)NC1CC1
Isomeric SMILES Cc1c(ccc(c1)c1c2nc(cc(n2nc1)NCC1CC(C1)(C)O)Oc1cnccc1)C(=O)NC1CC1
InChI InChI=1S/C28H30N6O3/c1-17-10-19(5-8-22(17)27(35)32-20-6-7-20)23-16-31-34-24(30-14-18-12-28(2,36)13-18)11-25(33-26(23)34)37-21-4-3-9-29-15-21/h3-5,8-11,15-16,18,20,30,36H,6-7,12-14H2,1-2H3,(H,32,35)
InChI Key PMQUGSPFUBGJCZ-UHFFFAOYSA-N
References
1. Liu Y, Laufer R, Patel NK, Ng G, Sampson PB, Li SW, Lang Y, Feher M, Brokx R, Beletskaya I et al.. (2016)
Discovery of Pyrazolo[1,5-a]pyrimidine TTK Inhibitors: CFI-402257 is a Potent, Selective, Bioavailable Anticancer Agent.
ACS Med Chem Lett, 7 (7): 671-5. [PMID:27437075]
2. Mason JM, Wei X, Fletcher GC, Kiarash R, Brokx R, Hodgson R, Beletskaya I, Bray MR, Mak TW. (2017)
Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer.
Proc Natl Acad Sci U S A, 114 (12): 3127-3132. [PMID:28270606]